MedsFacts.com




MedsFacts Meta-Analysis covering adverse side effect reports of GLUCAGON patients who developed THERAPY NON-RESPONDER.


Introduction: MedsFacts provides MD-approved analysis to help both patients and physicians accurately research and assess the risk-reward trade off for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration, social media, and MedsFacts user submissions. Between January 2004 and October 2012, 1 individuals taking GLUCAGON reported THERAPY NON-RESPONDER to the FDA. A total of 494 GLUCAGON drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

Topics covered: This page is designed to help you determine the relationship, if any, between GLUCAGON and THERAPY NON-RESPONDER. In doing so, we compare GLUCAGON with other drugs that cause THERAPY NON-RESPONDER, to help you evaluate whether or not GLUCAGON causes THERAPY NON-RESPONDER. Likewise, this page shows the most highly-reported side effects of GLUCAGON, so you can see if THERAPY NON-RESPONDER ranks among GLUCAGON's most well-known side effects.

The Dashboard explained: The Dashboard first shows general Summary Statistics for GLUCAGON and THERAPY NON-RESPONDER, such as the raw number and percentage of patients in FDA reports who used GLUCAGON and developed THERAPY NON-RESPONDER. Next, the Dashboard lists the most common reasons (indications) why GLUCAGON was prescribed for patients. We then display a pie-chart which shows, in aggregate, what we believe represents general physician opinion of the safety of GLUCAGON. This pie-chart summarizes, for all FDA reports covering GLUCAGON, whether or not the treating physician felt GLUCAGON (versus other drugs the patient was taking) was responsible for the adverse side-effects. After the pie-chart, we itemize the most common side effects in FDA studies covering GLUCAGON. You may click on any of these side effects to learn more about them, in general, or specifically for GLUCAGON. Finally, we identify the drugs most widely associated with GLUCAGON in FDA literature. You may also click on any of these drugs to view it's dashboard.

Dashboard view of our research literature concerning GLUCAGON :

Summary Statistics
Reports of GLUCAGON causing THERAPY NON-RESPONDER: 1
Reports of any side effect of GLUCAGON : 494
Percentage of GLUCAGON patients where THERAPY NON-RESPONDER is a reported side effect: 0.20242914979757%

FDA reports of any drug causing THERAPY NON-RESPONDER : 3953
Average percentage for all medicated patients where THERAPY NON-RESPONDER is reported as a complication: 0.024775070500525%
Most frequent diagnoses/indications for prescribing GLUCAGON:
PRODUCT USED FOR UNKNOWN INDICATION ( 44 patients )
HYPOGLYCAEMIA ( 33 patients )
DRUG USE FOR UNKNOWN INDICATION ( 20 patients )
DIABETES MELLITUS ( 11 patients )
TYPE 2 DIABETES MELLITUS ( 10 patients )
BLOOD GLUCOSE DECREASED ( 9 patients )
GASTROINTESTINAL ENDOSCOPIC THERAPY ( 8 patients )
DIAGNOSTIC PROCEDURE ( 8 patients )
INTESTINAL POLYPECTOMY ( 7 patients )
HYPERGLYCAEMIA ( 6 patients )
Physician opinion on GLUCAGON as adverse event culprit:

(* global)
Twitter feed for GLUCAGON - Pending/Beta





Basic reports are available, free of charge, in PDF format and are suitable for scientific publication. Further data and analytics are available upon request. We are in the process of adding new features to our site, including Q&A interface for patients to speak with experts on medication. Check back with us again in the near future to see.





Copyright 2013 MedsFacts
info@medsfacts.com
Privacy Policy
Terms of use